Inauhzin INZ cas 309271-94-1

Inauhzin is a potent SIRT inhibitor, which effectively reactivates p53 by inhibiting SIRT1 activity, promotes p53-dependent apoptosis of human cancer cells without causing apparently genotoxic stress. Moreover, Inauhzin stabilizes p53 by increasing p53 acetylation and preventing MDM2-mediated ubiquitylation of p53 in cells, though not directly in vitro. Remarkably, Inauhzin inhibits cell proliferation, induces senescence and tumour-specific apoptosis, and represses the growth of xenograft tumours derived from p53-harbouring H460 and HCT116 cells without causing apparent toxicity to normal tissues and the tumour-bearing SCID mice.

Related Prodcuts:

Etoposide; Etoposide phosphate; ML-323; BMH-21; Nexturastat A; TMP269; GSK2606414; ELR510444; Chidamide; CW069; Purvalanol A; Purvalanol B; JW55; Tenovin-6; Tenovin-6 HCL; RKI-1447; AZD2461; Tasquinimod

[1]. Zhang Q, et al. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol Med. 2012 Apr;4(4):298-312.

[2]. Zhang Y, et al. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther. 2012 Aug;13(10):915-24.

[3]. Nguyen D, et al. Reviving the guardian of the genome: Small molecule activators of p53. Pharmacol Ther. 2017 Oct;178:92-108.